🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-Muscle-Invasive Bladder Cancer (NMIBC)

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06995677Phase 248 sites📍 Homewood📍 Little Rock📍 Murrieta Tyra Biosciences, Inc · Tests: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer NCT07122414Phase 1, Phase 212 sites📍 Beijing📍 Beijing📍 Fuzhou Suzhou Forlong Biotechnology Co., Ltd · Tests: FL115, FL115+BCG LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve NCT04752722Phase 1, Phase 2102 sites📍 Birmingham📍 Scottsdale📍 Tucson enGene, Inc. · Tests: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy NCT07000084Phase 360 sites📍 Birmingham📍 Fairbanks📍 Gilbert Alliance for Clinical Trials in Oncology · Tests: BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) NCT06108492Phase 11 site📍 Shanghai Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-2005 Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer NCT07747740Phase 21 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: Gemcitabin, Docetaxel, Mitomicin C A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) NCT06637423Phase 1, Phase 213 sites📍 Bakersfield📍 Tampa📍 Chicago Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Rescue medication, Supportive care measures Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study NCT07339761NA1 site📍 Aarhus University of Aarhus · Tests: Sexological Support Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) NCT05825950n/a2 sites📍 Dallas📍 San Antonio University of Texas Southwestern Medical Center Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) NCT07763197n/a1 site📍 Austin Natera, Inc. Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors NCT07860398NA1 site📍 Herlev Optheras AS · Tests: ATLAS system ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG NCT06800963Phase 1, Phase 29 sites📍 Chandler📍 Sacramento📍 Atlanta ImmunityBio, Inc. · Tests: Intravesical Recombinant Mycobacterium (rMBCG) Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients NCT06696794Phase 33 sites📍 Wuhan📍 Wuhan📍 Xiangyang Shaogang Wang · Tests: Mitomycin C (MMC), Normal Saline (Placebo) A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) NCT06929286Phase 39 sites📍 Baltimore📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Nadofaragene Firadenovec, Gemcitabine, Docetaxel Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration NCT07307456Phase 21 site📍 Shanghai Changhai Hospital · Tests: Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT) Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) NCT05037279Phase 36 sites📍 Vancouver📍 Kingston📍 Toronto Verity Pharmaceuticals Inc. · Tests: Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 NCT06378242Phase 1, Phase 26 sites📍 Guangzhou📍 Wuhan📍 Changsha RemeGen Co., Ltd. · Tests: Disitamab Vedotin for injection A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer NCT06319820Phase 3193 sites📍 Little Rock📍 Los Alamitos📍 Los Angeles Janssen Research & Development, LLC · Tests: TAR-210, Gemcitabine, MMC Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC NCT07749924NA5 sites📍 Daqing📍 Nanchang📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, Adjuvant Intravesical Chemotherapy A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer NCT07804056Phase 31 site📍 Prague Hamlet Pharma AB · Tests: Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC NCT05410730Phase 1, Phase 21 site📍 Beijing Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-1501 Blue Light Cystoscopy With Cysview® Registry NCT02660645n/a23 sites📍 Birmingham📍 Phoenix📍 Los Angeles Photocure · Tests: Hexaminolevulinate hydrochloride (HCL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer NCT07206225Phase 168 sites📍 Birmingham📍 Birmingham📍 Birmingham Pfizer · Tests: PF-08052667, Sasanlimab, BCG, PF-02921367 Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 NCT07225127n/a6 sites📍 Tampa📍 Iowa City📍 Chapel Hill University of Washington
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy